| Literature DB >> 35845768 |
Hannah G Juncker1,2, Eliza J M Ruhé1, Aniko Korosi2, Johannes B van Goudoever1, Marit J van Gils3, Britt J van Keulen1.
Abstract
Importance: SARS-CoV-2-specific antibodies in human milk might protect the breastfed infant against COVID-19. One of the factors that may influence human milk antibodies is psychological stress, which is suggested to be increased in lactating women during the COVID-19 pandemic. Objective: To determine whether psychological stress is increased in lactating women during the COVID-19 pandemic, and if maternal stress is associated with the level of SARS-CoV-2-specific antibodies in human milk. Design: Population-based prospective cohort study. Setting: Data collection took place in the Netherlands between October 2020 and February 2021. Participants: Lactating women living in the Netherlands were eligible to participate in this study. In total, 2310 women were included. Exposures: Stress exposure during the COVID-19 pandemic was determined using the Perceived Stress Scale (PSS) questionnaire and maternal lifetime stress was determined by the Life Stressor Checklist - revised (LSC-r) questionnaire. Main Outcomes and Measures: Stress experience during the COVID-19 pandemic was compared with a pre-pandemic cohort. SARS-CoV-2-specific antibodies in human milk were measured using an Enzyme-Linked Immunosorbent Assay (ELISA) with the Spike protein of SARS-CoV-2. The association between maternal stress and human milk antibodies was determined using a multiple regression model.Entities:
Keywords: COVID-19; SARS-CoV-2; breast milk; lactation; passive immunity; stress
Year: 2022 PMID: 35845768 PMCID: PMC9280861 DOI: 10.3389/fnut.2022.923501
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Participants characteristics based on perceived stress scores (PSS) in participants with an ELISA confirmed SARS-CoV- 2 infection in serum or human milk.
|
| ||||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| Age mother – years* (± SD) | 33.1 (±3.8) ( | 33.2 (± 3.9) ( | 33.5 (± 3.9) ( | 33.0 (± 3.8) ( | 33.3 (± 4.1) ( | 0.46 |
| Body Mass Index** (IQR) | 23.3 (21.3–26.0) ( | 23.3 (21.4–25.9) ( | 23.1 (21.4–25.5) ( | 23.0 (21.1–25.8) ( | 23.6 (21.−26.2) ( | 0.16 |
| Chronic illness No. (%) | 306/2,224 (13.8) | 81/646 (12.5) | 18/182 (10.0) | 35/245 (14.3) | 28/219 (12.8) | 0.41 |
| Autoimmune disease No. (%) | 72/2,262 (3.2) | 15/646 (2.3) | 2/182 (1.1) | 7/245 (2.9) | 6/219 (2.7) | 0.46 |
| Psychological disease No. (%) | 408/2,221 (18.4) | 106/645 (16.4) | 20/182 (11.0) | 28/245 (11.4) | 58/218 (26.6) | 0.0001 |
| Smoking No. (%) | 42/2,196 (1.9) | 12/636 (1.9) | 0/179 (0) | 7/242 (2.9) | 5/215 (2.3) | 0.048 |
| Alcohol consumption No. (%) | 1,014/2,196 (46.2) | 338/636 (53.1) | 96/179 (53.6) | 136/242 (56.2) | 106/215 (49.3) | 0.33 |
| LSC-r score** (IQR) | 1.0 (0.0–3.0) ( | 1.0 (0.0-3.0) | 1.0 (0.0–2.0) ( | 1.0 (0.0–3.0) ( | 2.0 (1.0–4.0) ( | 0.0001 |
|
| 0.02 | |||||
| - Primary and lower secondary No. (%) | 31/2,263 (1.4) | 7/673 (1.0) | 3/182 (1.6) | 3/245 (1.2) | 1/219 (0.4) | |
| - Upper secondary No. (%) | 338/2,263 (14.9) | 114/673 (16.9) | 22/182 (12.1) | 37/245 (15.1) | 54/219 (24.6) | |
| - Bachelor equivalent No. (%) | 1,008/2,263 (44.5) | 291/673 (43.2) | 82/182 (45.1) | 99/245 (40.4) | 97/219 (44.3) | |
| - Master and Doctoral equivalent No. (%) | 842/2,263 (37.2) | 245/673 (36.4) | 73/182 (40.1) | 103/245 (42.0) | 65/219 (29.7) | |
|
| ||||||
| Age child – weeks** (IQR) | 34.0 (24.0–50.0) ( | 38.0 (25.0–59.0) | 37.0 (26.0–56.3) ( | 35.0 (23.3–55.0) ( | 42.0 (28.0–66.0) ( | 0.005 |
| GA at delivery – weeks** (IQR) | 40.0 (39.0-40.9) ( | 40.1 (39.0-40.9) | 40.0 (39.0-40.9) ( | 40.2 (39.3-41.0) ( | 40.0 (39.0–40.9) ( | 0.52 |
| Birth Weight – grams* (± SD) | 3,566 (±517) ( | 3,582 (± 517) ( | 3,579 (± 510) ( | 3,605 (± 517) ( | 3,562 (± 532) ( | 0.72 |
| Primipara No. (%) | 865/2,185 (39.6) | 244/635 (38.4) | 76/179 (42.5) | 92/242 (38.0) | 76/214 (35.5) | 0.37 |
| Sexe- Boy No. (%) | 1,071/2,233 (45.5) | 318/635 (50.0) | 83/179 (46.4) | 122/242 (50.4) | 113/214 (52.8) | 0.45 |
|
| ||||||
| Vaginal delivery No. (%) | 1,835/2,236 (82.1) | 532/635 (78.1) | 147/179 (82.1) | 204/242 (84.3) | 181/214 (84.6) | 0.79 |
| Instrumental delivery No. (%) | 129/2,236 (5.8) | 37/635 (5.8) | 14/179 (7.8) | 13/242 (5.4) | 10/214 (4.7) | 0.38 |
| Caesarian section No. (%) | 269/2,236 (12.0) | 84/635 (13.2) | 25/179 (13.9) | 34/242 (14.0) | 25/214 (11.7) | 0.72 |
Data are given as number/the total of participants who answered the specific question (%), mean (± Standard Deviation) and median (interquartile range: 25th percentile- 75th percentile). Data given as mean and median are given with the total amount of participants who filled out the specific question (N=). * = Data given as mean. ** = Data given as median. LSC-r score, life stressor checklist – revised calculated score; Education is classified according to the International Standard Classification of Education; GA, Gestational Age.
.
Figure 1Perceived Stress Scale (PSS) scores up to 12 months postpartum. This figure shows the increase in PSS scores over the first postpartum year. The box represents the interquartile range with median PSS scores. Whiskers present the data range (Q1/Q3 +/−1.5IQR). ·= outlier.
Figure 2Perceived Stress Scale (PSS) scores during and before the COVID-19 pandemic. In this figure, the PSS scores are displayed as mean (SD) of the specific postpartum group up to six months postpartum. Mean PSS scores of a U.S. cohort before the COVID-19 pandemic are obtained in Paul et al. (34). There were no differences between our study cohort and the pre-pandemic cohort.
The association between PSS scores and SARS-CoV-2-specific antibodies in human milk.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| Low - Moderate | 1.04 (0.96–1.13) | 0.34 | 1.06 (0.97–1.15) | 0.23 |
| Low - High | 1.04 (0.96–1.13) | 0.35 | 1.07 (0.98–1.17) | 0.15 |
| Moderate - High | 1.00 (0.92–1.08) | 0.98 | 1.01 (0.93–1.10) | 0.76 |
PSS, Perceived Stress Scale.
The regression model was adjusted for LSC-r scores, psychological disease, smoking, the age of the child and education level.
Figure 3Perceived Stress Scale (PSS) scores and SARS-CoV-2 specific Immunoglobuline A (IgA) in human milk. The boxes represent the interquartile range with median SARS-CoV-2 specific IgA in human milk for the different PSS groups. Whiskers present the data range (Q1/Q3 +/−1.5IQR). The dots indicate the individual measurements. No differences in SARS-CoV-2 specific human milk IgA were found between groups.
The association between LSC-r scores and SARS-CoV-2-specific antibodies in human milk.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| LSC-r score | 0.98 (0.97–1.00) | 0.08 | 0.98 (0.96–0.997) | 0.03 |
LSC-r, Life Stressor Checklist – revised.
We included age child, sex infant, parity, BMI, age mother to test for potential covariates. The age of the child was considered a confounder and was adjusted for in our model.
Figure 4Life Stressor Checklist-revised (LSC-r) scores and SARS-CoV-2 specific Immunoglobuline A (IgA) in human milk. The boxes represent the interquartile range with median SARS-CoV-2 specific IgA in human milk for the different LSC-r scores. Whiskers present the data range (Q1/Q3 +/−1.5IQR). The dots indicate the individual measurements. Multiple lineair regression models were used to determine the association between SARS-CoV-2-specific IgA in human milk and the LSC-r scores (adjusted p-value 0.03).